系统综述:药物治疗对成人X连锁低磷血症患者重要结局的疗效
本系统综述检索截至2023年5月的文献,评估布罗索尤单抗对比传统治疗或不治疗、以及传统治疗对比不治疗对成人X连锁低磷血症患者重要结局的影响。共纳入1项随机对照试验和2项观察性研究。布罗索尤单抗可能改善骨折/假性骨折愈合相关疼痛(中等确定性),但对直接疼痛指标几乎无影响(中等确定性),可能降低甲状旁腺切除术需求(低确定性),可能增加牙脓肿风险(低确定性)。成人中布罗索尤单抗与传统治疗无正式比较,传统治疗对比不治疗的证据极不确定。
要点
- 布罗索尤单抗可能改善骨折/假性骨折愈合相关疼痛(中等确定性)。
- 布罗索尤单抗对直接疼痛指标、疲劳、僵硬和活动能力几乎无影响。
- 布罗索尤单抗可能降低甲状旁腺切除术需求,但可能增加牙脓肿风险(低确定性)。
核心结论
- 成人中布罗索尤单抗与传统治疗之间无正式比较,传统治疗对比不治疗的证据极不确定。
- 本综述强调需要更多关于布罗索尤单抗和传统治疗对成人X连锁低磷血症患者重要结局长期影响的数据。
研究设计与样本
- 检索Embase、MEDLINE、Web of Science和Cochrane Central截至2023年5月的文献。
- 纳入随机对照试验和观察性研究,对象为18岁及以上临床或遗传确诊的X连锁低磷血症患者。
- 比较布罗索尤单抗与不治疗或传统治疗(磷酸盐和活性维生素D),以及传统治疗与不治疗。
- 两名评价者独立确定资格、提取数据并评估偏倚风险,采用GRADE方法评估证据确定性。
- 筛选4114条记录(去除重复后),评估254篇全文,最终纳入1项随机对照试验和2项观察性研究。
主要发现
- 布罗索尤单抗对比不治疗的随机对照试验偏倚风险低。
- 布罗索尤单抗可能改善骨折/假性骨折愈合相关疼痛(中等确定性),但对直接疼痛指标几乎无影响(中等确定性)。
- 布罗索尤单抗可能降低甲状旁腺切除术需求(低确定性),但对疲劳(高确定性)、僵硬(中等确定性)和活动能力(低确定性)在24周内几乎无影响。
- 布罗索尤单抗可能增加牙脓肿风险(低确定性)。
- 布罗索尤单抗对比传统治疗的间接证据确定性低;传统治疗对比不治疗的两项观察性研究偏倚风险高,证据确定性极低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 成人中布罗索尤单抗与传统治疗之间无正式比较。
- 传统治疗对比不治疗的证据极不确定。
- 布罗索尤单抗对比传统治疗的间接证据确定性低。
- 传统治疗对比不治疗的两项观察性研究偏倚风险高且证据确定性极低。
- 本综述强调需要更多关于长期影响的数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Understanding the effects of burosumab compared to conventional therapy or no treatment on patient-important outcomes in adults with X-linked hypophosphatemia (XLH) is essential to guide evidence-based treatment recommendations. OBJECTIVE: To examine the highest certainty evidence addressing the management of XLH in adults to inform treatment recommendations. METHODS: We searched Embase, MEDLINE, Web of Science, and Cochrane Central up to May 2023. Eligible studies included randomized controlled trials (RCTs) and observational studies of individuals aged 18+ with clinically or genetically confirmed XLH. Manuscripts comparing burosumab to no treatment or conventional therapy (phosphate and active vitamin D) and conventional therapy to no treatment were included. Two reviewers independently determined eligibility, extracted data, and assessed risk of bias (RoB). GRADE methodology was used to assess evidence certainty. RESULTS: We screened 4114 records, after removing duplicates, and assessed 254 full texts. One RCT and 2 observational studies were eligible. The RCT of burosumab vs no treatment had low RoB. Burosumab probably improves pain from fracture/pseudofracture healing (moderate certainty) but has little or no impact on direct pain measures (moderate certainty). Burosumab may reduce the need for parathyroidectomy (low certainty) but has little or no impact on fatigue (high certainty), stiffness (moderate certainty), and mobility (low certainty) over 24 weeks. Burosumab may increase dental abscess risk (low certainty). Indirect evidence comparing burosumab to conventional therapy provided low certainty regarding burosumab vs conventional therapy. Two observational studies on conventional therapy vs no treatment had high RoB and very low certainty regarding the impact of conventional therapy on patient-important outcomes. CONCLUSION: No formal comparisons between burosumab and conventional therapy in adults exist. Evidence for conventional therapy vs no treatment is very uncertain. Our review highlights the need for more data on the long-term effects of burosumab and conventional therapy on patient-important outcomes in adult patients with XLH.
引用
- Ali DS, Mirza RD, Alsarraf F, et al. Systematic Review: Efficacy of Medical Therapy on Outcomes Important to Adult Patients With X-Linked Hypophosphatemia. J Clin Endocrinol Metab. 2025. PMID: 39715351. doi:10.1210/clinem/dgae890
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。